Repare Therapeutics (NASDAQ:RPTX) Receives “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Repare Therapeutics (NASDAQ:RPTX) in a report released on Friday,Benzinga reports. They currently have a $10.00 price target on the stock.

Separately, Lifesci Capital raised Repare Therapeutics to a “strong-buy” rating in a research note on Monday, July 29th.

Repare Therapeutics Trading Up 2.9 %

Shares of NASDAQ:RPTX traded up $0.10 during midday trading on Friday, hitting $3.59. The stock had a trading volume of 70,883 shares, compared to its average volume of 162,200. Repare Therapeutics has a 1 year low of $2.71 and a 1 year high of $8.49. The stock has a 50 day moving average price of $3.35 and a two-hundred day moving average price of $3.40. The company has a market capitalization of $152.40 million, a PE ratio of -2.19 and a beta of 0.72.

Repare Therapeutics (NASDAQ:RPTX) last issued its earnings results on Tuesday, August 6th. The company reported ($0.82) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.03. Repare Therapeutics had a negative net margin of 99.76% and a negative return on equity of 31.11%. The company had revenue of $1.07 million for the quarter, compared to analyst estimates of $4.02 million. As a group, equities analysts expect that Repare Therapeutics will post -2.15 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Vontobel Holding Ltd. grew its holdings in shares of Repare Therapeutics by 20.0% during the third quarter. Vontobel Holding Ltd. now owns 24,000 shares of the company’s stock worth $83,000 after buying an additional 4,000 shares in the last quarter. Exchange Traded Concepts LLC lifted its stake in shares of Repare Therapeutics by 21.2% during the 3rd quarter. Exchange Traded Concepts LLC now owns 50,441 shares of the company’s stock worth $174,000 after purchasing an additional 8,809 shares during the period. Blue Owl Capital Holdings LP grew its position in shares of Repare Therapeutics by 8.0% in the second quarter. Blue Owl Capital Holdings LP now owns 3,372,499 shares of the company’s stock valued at $11,129,000 after purchasing an additional 250,000 shares during the period. Squarepoint Ops LLC increased its stake in Repare Therapeutics by 428.4% in the second quarter. Squarepoint Ops LLC now owns 142,974 shares of the company’s stock valued at $472,000 after purchasing an additional 115,916 shares during the last quarter. Finally, Marshall Wace LLP purchased a new stake in Repare Therapeutics in the 2nd quarter valued at about $273,000. Institutional investors and hedge funds own 85.09% of the company’s stock.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.